SiBone $SIBN Shares Bought by Goldman Sachs Group Inc.

Key Points

• Goldman Sachs Group Inc. increased its stake in SiBone by 28.4% in Q1, owning approximately 0.89% of the company worth $5.3 million.
• Recent trading activity includes significant insider sales, with Director John Gordon Freund selling over 12,000 shares and insider Anthony J. Recupero selling nearly 3,900 shares.
• SiBone's stock is down 3.6%, currently trading at $15.14, while the company reported an earnings per share of ($0.14), beating expectations.

Goldman Sachs Group Inc. boosted its holdings in shares of SiBone (NASDAQ:SIBN - Free Report) by 28.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 379,757 shares of the company's stock after purchasing an additional 83,919 shares during the period. Goldman Sachs Group Inc. owned about 0.89% of SiBone worth $5,328,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd acquired a new position in SiBone during the first quarter valued at $34,000. Virtus Fund Advisers LLC acquired a new position in SiBone during the fourth quarter valued at $40,000. GAMMA Investing LLC lifted its position in SiBone by 20,352.6% during the first quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock valued at $55,000 after purchasing an additional 3,867 shares during the period. Virtus Advisers LLC acquired a new position in SiBone during the first quarter valued at $58,000. Finally, Johnson Investment Counsel Inc. acquired a new position in SiBone during the first quarter valued at $148,000. 98.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director John Gordon Freund sold 12,132 shares of the company's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $15.99, for a total transaction of $193,990.68. Following the completion of the transaction, the director owned 91,767 shares in the company, valued at $1,467,354.33. This represents a 11.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Anthony J. Recupero sold 3,833 shares of the company's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $15.62, for a total transaction of $59,871.46. Following the transaction, the insider owned 275,288 shares of the company's stock, valued at approximately $4,299,998.56. This trade represents a 1.37% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 46,590 shares of company stock worth $765,137. Company insiders own 4.00% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Cantor Fitzgerald set a $25.00 price objective on shares of SiBone and gave the stock an "overweight" rating in a research report on Monday, August 11th. Wall Street Zen downgraded shares of SiBone from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $23.67.

SiBone Stock Down 3.6%

SIBN opened at $15.14 on Tuesday. SiBone has a twelve month low of $11.70 and a twelve month high of $20.05. The company has a quick ratio of 7.00, a current ratio of 8.38 and a debt-to-equity ratio of 0.21. The company has a 50-day moving average price of $16.57 and a 200 day moving average price of $16.39. The company has a market cap of $653.15 million, a PE ratio of -27.04 and a beta of 0.81.

SiBone (NASDAQ:SIBN - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.05. SiBone had a negative net margin of 12.83% and a negative return on equity of 14.20%. The firm had revenue of $48.63 million during the quarter, compared to the consensus estimate of $48.12 million. SiBone has set its FY 2025 guidance at EPS. Sell-side analysts expect that SiBone will post -0.78 earnings per share for the current fiscal year.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

Want to see what other hedge funds are holding SIBN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SiBone (NASDAQ:SIBN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.